drugset / Trial / NCT00159757

12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients

NCT00159757

Phase 4 Terminated 150 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

There has been evidence that ziprasidone is efficacious in decreasing the magnitude of both positive and negative symptoms of schizophrenia, and also effective in the treatment of depressive symptoms. It shows good tolerance with low incidence of extrapyramidal side effects and does not significantly influence body weight. As it has been shown that ziprasidone is efficacious and safe in patients who have been pretreated with other antipsychotic that has to be withdrawn either due to the side effects or not satisfied efficacy. The purpose of the study was to provide further evidence for the efficacy and safety of patients with schizophrenia and allow for psychiatrists in Hungary to gain experience with the drug before wide commercial availability.

Timeline

Start
2003-11
Primary completion
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule

Indications